

UK Health Check-up Market Size, Share & Trends Analysis Report By Test Type (Blood, Urine, Body Fluid Tests, Imaging-based Tests), By End-use (Enterprise, Individual), And Segment Forecasts, 2024 - 2030

<https://marketpublishers.com/r/UAD8EAE6B9E3EN.html>

Date: July 2024

Pages: 125

Price: US\$ 5,950.00 (Single User License)

ID: UAD8EAE6B9E3EN

Abstracts

This report can be delivered to the clients within 2 Business Days

UK Health Check-up Market Growth & Trends

The UK health check-up market size is anticipated to reach USD 3.0 billion by 2030, growing at a CAGR of 6.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of chronic diseases and the need to provide preventive screening solutions. For instance, according to UK Health indicators, the top four most prevalent chronic conditions in the UK for both men and women are allergies, hypertension, lower back disorders, and depression. Allergies emerged as the most frequently reported chronic issue among both genders, with rates of 30.4% for men and 36.0% for women. Nearly half of the UK population, comprising 45.7% of men and 50.1% of women, disclosed experiencing a persistent condition. A higher proportion of women (22.3%) indicated experiencing some activity limitations due to health issues in the past six months compared to men (18.5%).

Rising government initiatives to provide healthcare solutions is further anticipated to drive market growth. For instance, in February 2024, the National Health Service (NHS) announced the launch of a digital version of the health check-up program for citizens in England. This initiative, known as the NHS Health Check, is designed for individuals aged 40 to 74, which translates to approximately 15 million people

across the country. The check-up process typically involves an appointment with a general practitioner (GP), where patients are assessed for potential risks related to type 2 diabetes, strokes, kidney disease, and certain forms of dementia.

Moreover, the introduction of telemedicine in general healthcare practices has fueled the demand for home-based testing solutions. The healthcare ecosystem's digital connectivity framework has further empowered the market during the COVID-19 pandemic. The rising incidence of life-threatening diseases is a major driver for the market. This includes the growing prevalence of non-communicable diseases, such as diabetes, hypertension, cancer, and cardiovascular diseases. This combination of the increased availability of telemedicine and home-based testing, the escalating prevalence of life-threatening diseases, and the need for early detection of asymptomatic conditions are collectively expected to drive the growth and expansion of the market. These factors have enabled individuals to manage their health proactively and have contributed to the overall development of the healthcare ecosystem during the COVID-19 pandemic and beyond.

Furthermore, the rising strategic initiatives undertaken by the key players in the market, such as enhancing healthcare services and fostering collaborations between the public and private sectors, are expected to drive the overall development and expansion of the market. Additionally, the introduction of direct-to-customer testing solutions is anticipated to contribute to the growth and accessibility of check-up services during the forecast period. For instance, in June 2023, NHS announced the launch of home-based digital health checks. This new digital health check has been introduced with the aim of delivering an additional one million checks in the first four years.

UK Health Check-up Market Report Highlights

Blood, urine, body fluid tests segment dominated the test type segment and is anticipated to grow at the fastest growth rate over the forecast period owing to the rising adoption and usage of blood, urine, and body fluid samples in preventive care diagnosis.

Individuals dominated the end-use segment; this is attributed to the growing awareness for preventive health among the population.

Out-of-pocket dominated the individual end-use segment owing to the rising out-of-pocket spending expenditure by customers for personal

check-ups.

Enterprise segment held a significant share in end-use segment owing to the growing number of companies providing insurance to their employees.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Test Type
 - 1.2.2. End-use
 - 1.2.3. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
 - 1.7.3. Volume price analysis (Model 2)
 - 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
 - 2.2.1. Test Type and End-use outlook
- 2.3. Competitive Insights

CHAPTER 3. UK HEALTH CHECK-UP MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent market outlook

- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.1.1. Increasing prevalence of diseases
 - 3.2.1.2. Growing investments in population screening
 - 3.2.1.3. Growing geriatric population
 - 3.2.1.4. Adoption of digital technology
 - 3.2.2. Market Restraint Analysis
 - 3.2.2.1. High cost associated with screening
 - 3.2.2.2. Psychological Factors And Knowledge, Attitudes, & Beliefs
 - 3.2.3. Market challenge analysis
 - 3.2.3.1. Lack of awareness
 - 3.2.4. Market Opportunity Analysis
 - 3.2.4.1. Rising medical tourism
- 3.3. UK Health Check-up Market Analysis Tools
 - 3.3.1. Industry Analysis - Porter's Five Forces
 - 3.3.1.1. Supplier power
 - 3.3.1.2. Buyer power
 - 3.3.1.3. Substitution threat
 - 3.3.1.4. Threat of new entrant
 - 3.3.1.5. Competitive rivalry
 - 3.3.2. PESTEL Analysis
 - 3.3.2.1. Political landscape
 - 3.3.2.2. Technological landscape
 - 3.3.2.3. Economic landscape

CHAPTER 4. UK HEALTH CHECK-UP MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS

- 4.1. UK Health Check-up Market: Test Type Dashboard
- 4.2. UK Health Check-up Market: Test Type Movement Analysis
- 4.3. UK Health Check-up Market by Test Type, Revenue
- 4.4. Blood, Urine, Body Fluid Tests
 - 4.4.1. Blood, urine, body fluid tests market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Imaging-based tests (Xray, CT, US, MRI)
 - 4.5.1. Imaging based tests (Xray, CT, US, MRI) market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Non-imaging Tests (ECG, CPET, NCS, EMG, EEG)

4.6.1. Non-imaging tests (ECG, CPET, NCS, EMG, EEG) market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. UK HEALTH CHECK-UP MARKET: END-USE ESTIMATES & TREND ANALYSIS

5.1. UK Health Check-up Market: End-use Dashboard

5.2. UK Health Check-up Market: End-use Movement Analysis

5.3. UK Health Check-up Market by End-use, Revenue

5.4. Enterprise

5.4.1. Enterprise market estimates and forecasts 2018 to 2030 (USD Million)

5.4.2. Private (Corporate) Sector

5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

5.4.3. Government Sector

5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

5.4.4. Insurance

5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

5.5. Individual

5.5.1. Individual market estimates and forecasts 2018 to 2030 (USD Million)

5.5.2. Out of Pocket- Direct Payment for Health Check

5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

5.5.3. Individual Health Insurance Plan

5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 6. COMPETITIVE LANDSCAPE

6.1. Recent Developments & Impact Analysis, By Key Market Participants

6.2. Company/Competition Categorization

6.3. Vendor Landscape

6.3.1. List of key distributors and channel partners

6.3.2. Key customers

6.3.3. Key company market share analysis, 2023

6.3.4. Quest Diagnostics Incorporated

6.3.4.1. Company overview

6.3.4.2. Financial performance

6.3.4.3. Product benchmarking

6.3.4.4. Strategic initiatives

6.3.5. Laboratory Corporation of America Holdings

6.3.5.1. Company overview

- 6.3.5.2. Financial performance
- 6.3.5.3. Product benchmarking
- 6.3.5.4. Strategic initiatives
- 6.3.6. SYNLAB International GmbH
 - 6.3.6.1. Company overview
 - 6.3.6.2. Financial performance
 - 6.3.6.3. Product benchmarking
 - 6.3.6.4. Strategic initiatives
- 6.3.7. OPKO Health, Inc.
 - 6.3.7.1. Company overview
 - 6.3.7.2. Financial performance
 - 6.3.7.3. Product benchmarking
 - 6.3.7.4. Strategic initiatives
- 6.3.8. Eurofins Scientific
 - 6.3.8.1. Company overview
 - 6.3.8.2. Financial performance
 - 6.3.8.3. Product benchmarking
 - 6.3.8.4. Strategic initiatives
- 6.3.9. UNILABS
 - 6.3.9.1. Company overview
 - 6.3.9.2. Financial performance
 - 6.3.9.3. Product benchmarking
 - 6.3.9.4. Strategic initiatives
- 6.3.10. Sonic Healthcare Limited
 - 6.3.10.1. Company overview
 - 6.3.10.2. Financial performance
 - 6.3.10.3. Product benchmarking
 - 6.3.10.4. Strategic initiatives
- 6.3.11. ARUP Laboratories
 - 6.3.11.1. Company overview
 - 6.3.11.2. Financial performance
 - 6.3.11.3. Product benchmarking
 - 6.3.11.4. Strategic initiatives
- 6.3.12. Q2 Solutions
 - 6.3.12.1. Company overview
 - 6.3.12.2. Financial performance
 - 6.3.12.3. Product benchmarking
 - 6.3.12.4. Strategic initiatives

List Of Tables

LIST OF TABLES

Table 1 List of abbreviations

Table 2 UK health check-up market, by test type, 2018 - 2030 (USD Million)

Table 3 UK health check-up market, by end-use, 2018 - 2030 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Head And neck cancer therapeutics market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value chain-based sizing & forecasting
- Fig. 7 QFD modelling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 Market snapshot
- Fig. 10 Therapy type and route of administration segment snapshot
- Fig. 11 Distribution channel segment snapshot
- Fig. 12 Competitive landscape snapshot
- Fig. 13 Market dynamics
- Fig. 14 Porter's five forces analysis
- Fig. 15 PESTLE analysis
- Fig. 16 Head and neck cancer therapeutics market: Therapy type outlook & key takeaways
- Fig. 17 Head and neck cancer therapeutics market: Therapy type movement analysis
- Fig. 18 Global chemotherapy market, 2018 - 2030 (USD Million)
- Fig. 19 Global immunotherapy market, 2018 - 2030 (USD Million)
- Fig. 20 Global targeted therapy market, 2018 - 2030 (USD Million)
- Fig. 21 Head and neck cancer therapeutics market: Route of administration outlook & key takeaways
- Fig. 22 Head and neck cancer therapeutics market: Route of administration movement analysis
- Fig. 23 Global injectable market, 2018 - 2030 (USD Million)
- Fig. 24 Global oral market, 2018 - 2030 (USD Million)
- Fig. 25 Head and neck cancer therapeutics market: Distribution channel outlook & key takeaways
- Fig. 26 Head and neck cancer therapeutics market: Distribution channel movement analysis
- Fig. 27 Global retail & specialty pharmacies market, 2018 - 2030 (USD Million)
- Fig. 28 Global hospital pharmacies market, 2018 - 2030 (USD Million)
- Fig. 29 Global online pharmacies market, 2018 - 2030 (USD Million)

Fig. 30 Head and neck cancer therapeutics market revenue, by region, 2023 & 2030 (USD Million)

Fig. 31 Regional marketplace: Key takeaways

Fig. 32 Regional marketplace: Key takeaways

Fig. 33 North America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 34 Key country dynamics

Fig. 35 U.S. head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 36 U.S. oropharynx cancer: Estimated number of new cases, 2020 - 2040

Fig. 37 Key country dynamics

Fig. 38 Canada head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 39 Canada: oropharynx cancer: Estimated number of new cases, 2020 - 2040

Fig. 40 Key country dynamics

Fig. 41 Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 42 Key country dynamics

Fig. 43 UK head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 44 Lip, oral cavity cancer incidence, 2020 - 2030

Fig. 45 Key country dynamics

Fig. 46 Germany head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 47 Oropharynx cancer incidence, 2020 - 2030

Fig. 48 Germany insurance coverage

Fig. 49 Key country dynamics

Fig. 50 France head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 51 Lip, oral cavity cancer incidence, 2020 - 2030

Fig. 52 Key country dynamics

Fig. 53 Spain head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 54 Lip, oral cavity cancer incidence, 2020 - 2030

Fig. 55 Key country dynamics

Fig. 56 Italy head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 57 Larynx cancer incidence, 2020 - 2030

Fig. 58 Key country dynamics

- Fig. 59 Denmark head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 60 Oropharynx Cancer Incidence, 2020 - 2030
- Fig. 61 Key country dynamics
- Fig. 62 Sweden head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 63 Lip, oral cavity cancer incidence, 2020 - 2030
- Fig. 64 Key country dynamics
- Fig. 65 Norway head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 66 Lip, oral cavity cancer incidence, 2020 - 2030
- Fig. 67 Rest of Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 68 Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 69 Key country dynamics
- Fig. 70 Japan head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 71 Japan pharmaceutical registration
- Fig. 72 Key country dynamics
- Fig. 73 China head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 74 Nasopharynx cancer incidence, 2020 - 2030
- Fig. 75 Regulatory details: China
- Fig. 76 Exclusivity formula
- Fig. 77 Key country dynamics
- Fig. 78 India head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 79 Lip, oral cavity cancer incidence, 2020 - 2030
- Fig. 80 Registration details: India
- Fig. 81 Key country dynamics
- Fig. 82 Australia head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 83 Lip, Oral Cavity Cancer incidence, 2020 to 2030
- Fig. 84 Drug pricing: Australia
- Fig. 85 Contribution of PBS by disease
- Fig. 86 Key country dynamics
- Fig. 87 Thailand head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)

- Fig. 88 Nasopharynx Cancer incidence, 2020 to 2030
- Fig. 89 Key country dynamics
- Fig. 90 South Korea head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 91 Lip, Oral Cavity Cancer incidence 2020 to 2030
- Fig. 92 Reimbursement scenario: South Korea
- Fig. 93 Rest of Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 94 Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 95 Key country dynamics
- Fig. 96 Brazil head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 97 Larynx Cancer Incidence, 2020 to 2030
- Fig. 98 Regulatory framework
- Fig. 99 Reimbursement scenario
- Fig. 100 Key country dynamics
- Fig. 101 Mexico head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 102 Mexico: oropharynx cancer: Estimated number of new cases, 2020 - 2040
- Fig. 103 Argentina head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 104 Larynx cancer incidence, 2020 to 2030
- Fig. 105 Argentina pharmaceuticals registration details
- Fig. 106 Argentina pharmaceuticals reimbursement details
- Fig. 107 Rest of Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 108 MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 109 Key country dynamics
- Fig. 110 South Africa head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 111 Lip, oral cavity cancer incidence, 2020 - 2030
- Fig. 112 Regulatory framework: South Africa
- Fig. 113 Regulatory framework: South Africa drug registration fees
- Fig. 114 Key country dynamics
- Fig. 115 Saudi Arabia head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 116 Nasopharynx cancer incidence, 2020 to 2030

Fig. 117 Key country dynamics

Fig. 118 UAE head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 119 Lip, oral cavity cancer incidence, 2020 - 2030

Fig. 120 Key country dynamics

Fig. 121 Kuwait head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 122 Lip, oral cavity cancer incidence, 2020 - 2030

Fig. 123 Regulatory framework: Kuwait

Fig. 124 Rest of MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 125 Key company categorization

Fig. 126 Company market share analysis, 2023

Fig. 127 Strategic framework

I would like to order

Product name: UK Health Check-up Market Size, Share & Trends Analysis Report By Test Type (Blood, Urine, Body Fluid Tests, Imaging-based Tests), By End-use (Enterprise, Individual), And Segment Forecasts, 2024 - 2030

Product link: <https://marketpublishers.com/r/UAD8EAE6B9E3EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UAD8EAE6B9E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970